Home > Resources > Whitepapers > The importance of COPQ for the pharmaceutical industry

The importance of COPQ for the pharmaceutical industry

As any senior executive within an organisation knows, the reduction of waste and, more importantly, the cost associated with that waste can have a major effect on any business. Whilst some waste is unavoidable, an executive can begin to implement principals to eliminate this additional “cost of poor quality” (COPQ) by considering which costs would be eliminated if every system, process and product in the business were run at maximum optimisation. In the pharmaceutical industry, it is not uncommon for such costs to range between 25 and 40 percent of total sales revenue1 and yet reducing the COPQ is not a well understood or implemented practice.

Spotlight

Mental Health Care (UK) Ltd

Mental Health Care UK (MHC) is one of the UK’s top 50 providers of support to individuals with learning disabilities,mental health issues, behaviours that challenge and autism. In our calm and safe residential homes and hospitals we believe in a research based approach to our services. Residents with learning disabilities, behaviours that challenge, mental health issues, and autism will benefit from an approach that uses Active Support, Person Centred Planning and Positive Behavioural Support to enable our residents to be in control, make decisions and achieve what’s important for them.

OTHER WHITEPAPERS

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

State of the Global Biotech Landscape: Where the Opportunities Lie

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

IoT To The Rescue For Biotech & Pharma Manufacturing

whitePaper | April 7, 2020

The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.

Spotlight

Mental Health Care (UK) Ltd

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference